

Background and importance Nutritional support by the parenteral route aims to prevent and recover nutritional deficits whenever enteral nutrition is insufficient or contraindicated. Caloric requirements must be calculated according to the degree of metabolic stress, percentage of ideal weight and extent of intestinal failure. During parenteral nutrition (PN) complications such as hydroelectrolyte and metabolic imbalance may occur (eg, refeeding syndrome), which increase morbidity and mortality among patients.

Aim and objectives Monitoring the effectiveness of the protocol established in 2006 that provides for the PN onset within 72 hours with caloric restriction (in the first 24 hours starts with 50% of caloric needs, in 48 hours with 75%, and in 72 hours and following with 100%), as well as evaluating compliance with the recommendations of the American Society for Parenteral and Enteral Nutrition/European Society for Clinical Nutrition and Metabolism (ASPEN/ESPEN) PN guidelines.

Material and methods Retrospective analysis of biochemical parameters (albumin, total protein, C-reactive protein (CRP), serum creatinine (Cr), potassium, phosphate and magnesium) in patients with PN. Data were collected through the patient's clinical records and the calculation of nutritional needs was carried out using the Harris–Benedict formula.

Results Forty patients (14 women and 26 men) were analysed in the period April–August 2021 (age 72 ± 12 years). The majority of patients were in Surgery Ward (78% patients). PN bags administered: 82% 1600 kcal, 13% 2200 kcal and 5% 1400 kcal. Gastric neoplasms and peritonitis were the main diagnoses associated with NP. The average onset of NP administration was 9 ± 7 days. All patients showed high CRP (>5 mg/dL), low total protein (<6.6 g/dL) and 85% of patients showed hypoalbuminaemia at onset of PN. Although, daily analyses of the recommended electrolytes were not performed, it was observed that 20% developed hypokalaemia, 18% hypophosphataemia and 8% hypomagnesaemia. No refeeding syndrome was diagnosed in the studied sample.

Conclusion and relevance The start of 72-hour PN protocol with caloric restriction allowed avoidance of the refeeding syndrome, which usually appears within the first 7 days after the onset of PN. The compliance of ESPEN/ASPEN guidelines for daily monitoring of electrolytes was not observed for all patients. So, it will be proposed to reinforce pharmaceutical interventions, as well as developing together with the clinical team a monitoring protocol for patients under PN.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. ASPEN Consensus Recommendations for Refeeding Syndrome. *Nutr Clin Pract* 2020;35(6). doi: 10.1002/ncp.10474.

Conflict of interest No conflict of interest

5PSQ-077 BEVACIZUMAB VERSUS BIOSIMILAR: USE IN OPHTHALMOLOGY

¹A Alcobia*, ¹S Domingos, ¹C Canário, ¹H Mestre, ¹T Barreira, ¹M Lobanov, ²M Pereira, ²F Moraes. ¹Hospital Garcia de Orta, Hospital Pharmacy, Almada, Portugal; ²Hospital Garcia de Orta, Ophthalmology Department, Almada, Portugal

10.1136/ejhpharm-2022-eahp.300

Background and importance Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) antibody currently used in ophthalmology as an off-label treatment for age-related macular degeneration, diabetic macular oedema, and oedema

secondary to retinal vein occlusion. Despite its off-label use, various studies have shown similar results between bevacizumab and other anti-VEGF treatments. With the availability of a biosimilar with the same presentation and excipients, a switch programme was implemented.

Aim and objectives Compare the effectiveness of bevacizumab Avastin versus biosimilar MVASI in the ophthalmology service.

Material and methods A retrospective observational study analysed 122 patients (65 male, 57 female) who underwent the first intravitreal administration (IVI) between January 2020 and March 2021. Data from best corrected visual acuity (BCVA) and central subfield thickness (CST) were collected. Exclusion criteria were the absence of registration of optical coherence tomography (OCT) and BCVA or failure to comply to three loading dose injectins. The patients were divided into three groups: group 1, 63 patients (3IVI of Avastin), group 2, 30 patients (3 IVI of biosimilar) and group 3, 29 patients (3 IVI, transitioning from Avastin to the biosimilar, either with 1 or 2 Avastin administrations). Manova test was used to determine statistically significant differences among the groups, taking into account the values of BCVA and CST, patients' age, and the number of days between the last registration prior to the first IVI and the first posterior to the third IVI, without any corrections for differences between groups. T-tests were used to obtain graphic representations of the results.

Results The sample analysed had a mean age of 71.56 years. After three IVI, in group 1, there was 82% of improvement for CST; in group 2 there was 92% and for group 3 there was 84%. MANOVA test was performed showing no statistical significance in BCVA and OCT central thickness difference between the three groups (Willk's lambda ($p=0.238$)) neither between MVASI group with the Avastin group (Hotelling's T-squared test ($p=0.114$, equal covariance)).

Conclusion and relevance We found no difference, for the analysed sample, in outcomes and adverse effects between Avastin and biosimilar MVASI, which proves the possibility of replacing Avastin with the biosimilar MVASI already in use in oncological patients, ensuring a significant cost reduction.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

5PSQ-078 THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA

¹FJ Juliá Luna*, ¹MDP Briceño Casado, ²MD Gil-Sierra, ¹B Criado Rubio, ¹FJ Alonso Salmeron, ¹C Piqueras Romero. ¹Hospital General Universitario Nuestra Señora del Prado, Pharmacy, Talavera de La Reina, Spain; ²Hospital Universitario de Puerto Real, Pharmacy, Puerto Real, Spain

10.1136/ejhpharm-2022-eahp.301

Background and importance Venous thromboembolic disease is a frequent and important complication in haematologic patients and is associated with a worse prognosis. Thromboembolism prophylaxis (TP) is recommended in patients with multiple myeloma (MM) and treated with immunomodulators.

Aim and objectives To assess the adequacy of TP in patients with MM at treatment onset with thalidomide and lenalidomide according to thromboembolic risk.

Material and methods Descriptive retrospective study was conducted (January 2016–January 2021) including patients with MM in treatment with thalidomide or lenalidomide.